Search

Your search keyword '"Ader, Florence"' showing total 468 results

Search Constraints

Start Over You searched for: Author "Ader, Florence" Remove constraint Author: "Ader, Florence" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
468 results on '"Ader, Florence"'

Search Results

51. Additional file 1 of Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

53. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

55. Implementation of a Centralized Pharmacovigilance System in Multi-Country European Clinical Trials: Points to Consider for Academic Sponsors and Lessons Learnt from EU-Response and Connect4Children Consortia

58. Immunocompromised patients have been neglected in COVID-19 trials: a call for action

60. P397 Influence of underlying conditions on disease presentation and diagnostic strategy during pulmonary mucormycosis: Anational study of 114 cases

61. COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency

62. Prognosis and factors associated with disseminated nocardiosis: a ten-year multicenter study

63. Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants

64. A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation

66. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study

67. Prise en charge thérapeutique des tuberculoses résistantes

68. Mycobacterium tuberculosis genetic features associated with pulmonary tuberculosis severity

70. Smoking‐associated morbidities on computed tomography lung cancer screens in HIV‐infected smokers

71. Clinical Presentation, Diagnosis, and Bacterial Epidemiology of Peritoneal Tuberculosis in Two University Hospitals in France

72. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

73. In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion

74. Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

75. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

77. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial

78. Disappearance of FDG uptake on PET scan after antimicrobial therapy could help for the diagnosis of Coxiella burnetii spondylodiscitis

79. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

80. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

81. Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7

82. Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.

83. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

84. Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial

85. Implementation of a complex bone and joint infection phage therapy centre in France: lessons to be learned after 4 years' experience

86. Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials

87. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

89. Reactivation of Clostridium tertium bone infection 30 years after the Iran–Iraq war

90. A 22-year-old woman with right lumpy jaw syndrome and fistula

91. In-depth immunophenotyping with mass cytometry during TB treatment reveals non-canonical T-cell subsets associated with sputum culture conversion

92. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

93. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter?

94. Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference

95. Pristinamycin in the treatment of MSSA bone and joint infection

96. Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study

97. Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion

98. Interferon-[gamma] autoantibodies as predisposing factor for nontuberculous mycobacterial infection

100. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France

Catalog

Books, media, physical & digital resources